Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Hey, Look at That Data Over There

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Oh, the irony.

Human Genome Sciences (Nasdaq: HGSI  ) is doing battle with GlaxoSmithKline (NYSE: GSK  ) , which is looking to take over the biotech without management's blessing. The riff has escalated from a civil tiff to a more substantive battle.

So whose press release does Human Genome point to in its quest to prove that it's more valuable than Glaxo's lowball offer? None other than Glaxo's.

The two are partners on more than just the lupus drug Benlysta. Glaxo is also developing a couple of Human Genome-discovered drugs currently in late-stage trials: diabetes drug albiglutide and darapladib, for hardening of the arteries.

So when Glaxo presented data on albiglutide at the American Diabetes Association meeting, Human Genome felt compelled to issue an FYI press release pointing out the data. The title of the press release literally began, "FYI from Human Genome Sciences."

Albiglutide is a GLP-1 agonist in the same class as Amylin Pharmaceuticals' (Nasdaq: AMLN  ) Byetta and Bydureon and Novo Nordisk's (NYSE: NVO  ) Victoza. In one of the phase-3 trials presented at ADA, albiglutide performed just as well as Eli Lilly's (NYSE: LLY  ) Humalog insulin after patients had been on the drugs for a year. Unfortunately, another trial failed to prove albiglutide was as good as Victoza. However, there are still six more phase-3 trials testing albiglutide against other medications to find a niche.

Human Genome is entitled to another $150 million in milestone payments and single-digit royalties on worldwide sales of the drug. Unfortunately, the potential for milestones and royalties isn't all that attractive to would-be suitors because there's nowhere for acquirers to add value, as Glaxo is in full control of the molecule.

Increasingly good data for albiglutide from the other trials would make Human Genome more valuable to Glaxo, but as long as it's the only bidder, there's no reason for Glaxo to increase its offer by more than a token amount.

While Human Genome tries to drive a hard bargain, there's a worry that it could drive away its suitor, which would be bad news if another bidder doesn't step up. After Roche walked away from its offer to buy Illumina, shares in the genomic chip and sequencing specialist have slipped down near the pre-offer price.

David Gardner and his team at Rule Breakers aren't counting on an acquisition to get solid returns from one of their recent health-care picks. Find out what it is and why they like it in the Fool's free report, "Discover the Next Rule-Breaking Multibagger."

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Illumina. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1910417, ~/Articles/ArticleHandler.aspx, 10/22/2016 2:08:46 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 16 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:02 PM
GSK $41.13 Down -0.30 -0.72%
GlaxoSmithKline CAPS Rating: ***
HGSI.DL $0.00 Down +0.00 +0.00%
Human Genome Scien… CAPS Rating: **
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***
NVO $41.50 Up +0.46 +1.12%
Novo Nordisk CAPS Rating: *****